Replimune Group Inc. Common Stock (REPL)
Stock · NASDAQ · Health Care
$10.87as of 10/16/2026
Price chart
Active signals
REPL Signal Track Record
How signals performed across all stocks →What REPL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | +9.0% | 60% | September 29, 2026 |
| Bollinger Band BreakdownActive now | 26 | -2.9% | 42% | September 10, 2026 |
| Bollinger Band Breakout | 21 | +0.9% | 52% | May 29, 2026 |
| 200-Day Moving Average TouchActive now | 11 | +4.5% | 55% | March 31, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 465
- Website
- www.replimune.com/
Fundamentals
- 1-day range
- $10.81$11.73
- Market cap
- $1.08B
- P/E (trailing)
- —
- P/E (forward)
- -5.97
- EPS (trailing)
- $-3.16
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 4.04M
Forecasts
6 analyst ratings
Replimune Group Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- REPLReplimune Group Inc. Common Stock$10.86▼ 7.57%Market cap $1.08BP/E —$1.5$16.33
- CGEMCullinan Therapeutics Inc. Common Stock$12.93▼ 7.64%Market cap $1.10BP/E —$6.73$23.19
- ODTXOdyssey Therapeutics Inc. Common Stock$17.17▼ 2.28%Market cap $1.04BP/E —$15.1$29.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- SANASana Biotechnology Inc. Common Stock$2.27▼ 8.28%Market cap $948.97MP/E —$2.32$6.55
- ATTOAttovia Therapeutics Inc. Common Stock$13.73▼ 7.10%Market cap $928.90MP/E 0.00$14.23$28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| REPL Replimune Group Inc. Common Stock | $1.08B | — | $10.86 | ▼ 7.57% | $1.5$16.33 |
| CGEM Cullinan Therapeutics Inc. Common Stock | $1.10B | — | $12.93 | ▼ 7.64% | $6.73$23.19 |
| ODTX Odyssey Therapeutics Inc. Common Stock | $1.04B | — | $17.17 | ▼ 2.28% | $15.1$29.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| SANA Sana Biotechnology Inc. Common Stock | $948.97M | — | $2.27 | ▼ 8.28% | $2.32$6.55 |
| ATTO Attovia Therapeutics Inc. Common Stock | $928.90M | 0.00 | $13.73 | ▼ 7.10% | $14.23$28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Astley-Sparke Philip · August 20, 2026 · Gift50.0K
- BAKER BROS. ADVISORS LP · August 11, 2026 · Buy2.61M @ $12.06
- BAKER BROS. ADVISORS LP · August 11, 2026 · Buy126.4K @ $12.06
- Sushil Patel · August 10, 2026 · Sale39.3K @ $12.97
- Hill Emily Luisa · August 10, 2026 · Sale11.4K @ $12.97
- Xynos Konstantinos · August 10, 2026 · Sale11.4K @ $12.97
- Schwendenman Andrew · August 10, 2026 · Sale7.6K @ $12.97
- Sarchi Christopher · June 1, 2026 · Sale12.0K @ $9.24
- Xynos Konstantinos · May 18, 2026 · Sale14.0K @ $5.08
- Schwendenman Andrew · May 18, 2026 · Sale7.9K @ $5.08
- Sarchi Christopher · May 18, 2026 · Sale8.6K @ $5.08
- Sushil Patel · May 18, 2026 · Sale37.3K @ $5.08
- Hill Emily Luisa · May 18, 2026 · Sale7.8K @ $5.08
- Astley-Sparke Philip · May 18, 2026 · Sale17.7K @ $5.08
Institutional Ownership
March 31, 2026
- Total shares held
- 86.58M
- Total value held
- $595.23M
- Institutional holders
- 183
- Unknown11.05M
- Unknown8.12M
- Unknown7.36M
- Unknown6.24M
- Unknown4.22M
- Unknown3.78M
- Unknown2.81M
- Unknown2.76M
- Unknown2.34M
- Unknown2.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views
Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.